{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:27:08Z","timestamp":1792679228247,"version":"4.5.0"},"reference-count":232,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T00:00:00Z","timestamp":1348444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T00:00:00Z","timestamp":1348444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/nrd3810","type":"journal-article","created":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T06:09:48Z","timestamp":1348466988000},"page":"790-811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1391,"title":["Targeting the TGF\u03b2 signalling pathway in disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Rosemary J.","family":"Akhurst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,24]]},"reference":[{"key":"BFnrd3810_CR1","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/nrm2297","volume":"8","author":"B Schmierer","year":"2007","unstructured":"Schmierer, B. & Hill, C. S. TGF\u03b2\u2013SMAD signal transduction: molecular specificity and functional flexibility. Nature Rev. Mol. Cell Biol. 8, 970\u2013982 (2007).","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnrd3810_CR2","volume-title":"The TGF-\u03b2 Family","author":"R Derynck","year":"2008","unstructured":"Derynck, R. & Miyazono, K. (eds) The TGF-\u03b2 Family (Cold Spring Harbor Press, 2008)."},{"key":"BFnrd3810_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ncb434","volume":"9","author":"R Derynck","year":"2007","unstructured":"Derynck, R. & Akhurst, R. J. Differentiation plasticity regulated by TGF-\u03b2 family proteins in development and disease. Nature Cell Biol. 9, 1000\u20131004 (2007).","journal-title":"Nature Cell Biol."},{"key":"BFnrd3810_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","volume":"10","author":"RA Flavell","year":"2010","unstructured":"Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Limon, P. The polarization of immune cells in the tumour environment by TGF\u03b2. Nature Rev. Immunol. 10, 554\u2013567 (2010).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrd3810_CR5","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.1073\/pnas.0602581103","volume":"103","author":"JH Mao","year":"2006","unstructured":"Mao, J. H. et al. Genetic variants of Tgfb1 act as context-dependent modifiers of mouse skin tumor susceptibility. Proc. Natl Acad. Sci. USA 103, 8125\u20138130 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3810_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2008.302","volume":"19","author":"X Guo","year":"2009","unstructured":"Guo, X. & Wang, X. F. Signaling cross-talk between TGF-\u03b2\/BMP and other pathways. Cell Res. 19, 71\u201388 (2009).","journal-title":"Cell Res."},{"key":"BFnrd3810_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cytogfr.2011.11.006","volume":"22","author":"A Conidi","year":"2011","unstructured":"Conidi, A. et al. Few Smad proteins and many Smad-interacting proteins yield multiple functions and action modes in TGF\u03b2\/BMP signaling in vivo. Cytokine Growth Factor Rev. 22, 287\u2013300 (2011).","journal-title":"Cytokine Growth Factor Rev."},{"key":"BFnrd3810_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ng0804-790","volume":"36","author":"RJ Akhurst","year":"2004","unstructured":"Akhurst, R. J. TGF\u03b2 signaling in health and disease. Nature Genet. 36, 790\u2013792 (2004).","journal-title":"Nature Genet."},{"key":"BFnrd3810_CR9","unstructured":"Freimuth, J. et al. Epistatic interactions between Tgfb1 and genetic loci, Tgfbm2 and Tgfbm3, determine susceptibility to an asthmatic stimulus. Proc. Natl Acad. Sci. USA (in the press)."},{"key":"BFnrd3810_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ijrobp.2008.02.046","volume":"71","author":"MS Anscher","year":"2008","unstructured":"Anscher, M. S. et al. Small molecular inhibitor of transforming growth factor-\u03b2 protects against development of radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 71, 829\u2013837 (2008).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrd3810_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng1116","volume":"33","author":"ER Neptune","year":"2003","unstructured":"Neptune, E. R. et al. Dysregulation of TGF-\u03b2 activation contributes to pathogenesis in Marfan syndrome. Nature Genet. 33, 407\u2013411 (2003).","journal-title":"Nature Genet."},{"key":"BFnrd3810_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1126\/science.1124287","volume":"312","author":"JP Habashi","year":"2006","unstructured":"Habashi, J. P. et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312, 117\u2013121 (2006).","journal-title":"Science"},{"key":"BFnrd3810_CR13","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.1073\/pnas.1633291100","volume":"100","author":"AB Roberts","year":"2003","unstructured":"Roberts, A. B. & Wakefield, L. M. The two faces of transforming growth factor \u03b2 in carcinogenesis. Proc. Natl Acad. Sci. USA 100, 8621\u20138623 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3810_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massague","year":"2008","unstructured":"Massague, J. TGF\u03b2 in cancer. Cell 134, 215\u2013230 (2008).","journal-title":"Cell"},{"key":"BFnrd3810_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cytogfr.2005.09.009","volume":"17","author":"L Levy","year":"2006","unstructured":"Levy, L. & Hill, C. S. Alterations in components of the TGF-\u03b2 superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 17, 41\u201358 (2006).","journal-title":"Cytokine Growth Factor Rev."},{"key":"BFnrd3810_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/08977194.2011.595411","volume":"29","author":"LJ Hawinkels","year":"2011","unstructured":"Hawinkels, L. J. & Ten Dijke, P. Exploring anti-TGF-\u03b2 therapies in cancer and fibrosis. Growth Factors 29, 140\u2013152 (2011).","journal-title":"Growth Factors"},{"key":"BFnrd3810_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/07853890600919911","volume":"38","author":"KA Harradine","year":"2006","unstructured":"Harradine, K. A. & Akhurst, R. J. Mutations of TGF\u03b2 signaling molecules in human disease. Ann. Med. 38, 403\u2013414 (2006).","journal-title":"Ann. Med."},{"key":"BFnrd3810_CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1242\/dev.111.1.131","volume":"111","author":"FA Millan","year":"1991","unstructured":"Millan, F. A., Denhez, F., Kondaiah, P. & Akhurst, R. J. Embryonic gene expression patterns of TGF \u03b21, \u03b22 and \u03b23 suggest different developmental functions in vivo. Development 111, 131\u2013143 (1991).","journal-title":"Development"},{"key":"BFnrd3810_CR19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1073\/pnas.90.2.770","volume":"90","author":"AB Kulkarni","year":"1993","unstructured":"Kulkarni, A. B. et al. Transforming growth factor \u03b21 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90, 770\u2013774 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3810_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/359693a0","volume":"359","author":"MM Shull","year":"1992","unstructured":"Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-\u03b21 gene results in multifocal inflammatory disease. Nature 359, 693\u2013699 (1992).","journal-title":"Nature"},{"key":"BFnrd3810_CR21","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1242\/dev.121.6.1845","volume":"121","author":"MC Dickson","year":"1995","unstructured":"Dickson, M. C. et al. Defective haematopoiesis and vasculogenesis in transforming growth factor-\u03b21 knock out mice. Development 121, 1845\u20131854 (1995).","journal-title":"Development"},{"key":"BFnrd3810_CR22","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1242\/dev.124.13.2659","volume":"124","author":"LP Sanford","year":"1997","unstructured":"Sanford, L. P. et al. TGF\u03b22 knockout mice have multiple developmental defects that are non-overlapping with other TGF\u03b2 knockout phenotypes. Development 124, 2659\u20132670 (1997).","journal-title":"Development"},{"key":"BFnrd3810_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/ng1295-409","volume":"11","author":"G Proetzel","year":"1995","unstructured":"Proetzel, G. et al. Transforming growth factor-\u03b23 is required for secondary palate fusion. Nature Genet. 11, 409\u2013414 (1995).","journal-title":"Nature Genet."},{"key":"BFnrd3810_CR24","doi-asserted-by":"crossref","first-page":"26775","DOI":"10.1016\/S0021-9258(18)47086-X","volume":"269","author":"S Schultz-Cherry","year":"1994","unstructured":"Schultz-Cherry, S., Ribeiro, S., Gentry, L. & Murphy-Ullrich, J. E. Thrombospondin binds and activates the small and large forms of latent transforming growth factor-\u03b2 in a chemically defined system. J. Biol. Chem. 269, 26775\u201326782 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3810_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0092-8674(00)80545-0","volume":"96","author":"JS Munger","year":"1999","unstructured":"Munger, J. S. et al. The integrin \u03b1v\u03b26 binds and activates latent TGF \u03b21: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319\u2013328 (1999).","journal-title":"Cell"},{"key":"BFnrd3810_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature10152","volume":"474","author":"M Shi","year":"2011","unstructured":"Shi, M. et al. Latent TGF-\u03b2 structure and activation. Nature 474, 343\u2013349 (2011).","journal-title":"Nature"},{"key":"BFnrd3810_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi, Y. & Massague, J. Mechanisms of TGF-\u03b2 signaling from cell membrane to the nucleus. Cell 113, 685\u2013700 (2003).","journal-title":"Cell"},{"key":"BFnrd3810_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4161\/rna.8.1.14299","volume":"8","author":"BN Davis-Dusenbery","year":"2011","unstructured":"Davis-Dusenbery, B. N. & Hata, A. Smad-mediated miRNA processing: a critical role for a conserved RNA sequence. RNA Biol. 8, 71\u201376 (2011).","journal-title":"RNA Biol."},{"key":"BFnrd3810_CR29","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1101\/gad.10.19.2462","volume":"10","author":"M Oft","year":"1996","unstructured":"Oft, M. et al. TGF-\u03b21 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10, 2462\u20132477 (1996).","journal-title":"Genes Dev."},{"key":"BFnrd3810_CR30","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.febslet.2006.04.033","volume":"580","author":"J Massague","year":"2006","unstructured":"Massague, J. & Gomis, R. R. The logic of TGF\u03b2 signaling. FEBS Lett. 580, 2811\u20132820 (2006).","journal-title":"FEBS Lett."},{"key":"BFnrd3810_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/35043051","volume":"1","author":"J Massague","year":"2000","unstructured":"Massague, J. How cells read TGF-\u03b2 signals. Nature Rev. Mol. Cell Biol. 1, 169\u2013178 (2000).","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnrd3810_CR32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1139\/o02-161","volume":"80","author":"A Mehra","year":"2002","unstructured":"Mehra, A. & Wrana, J. L. TGF-\u03b2 and the Smad signal transduction pathway. Biochem. Cell Biol. 80, 605\u2013622 (2002).","journal-title":"Biochem. Cell Biol."},{"key":"BFnrd3810_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/cr.2008.316","volume":"19","author":"D Padua","year":"2009","unstructured":"Padua, D. & Massague, J. Roles of TGF\u03b2 in metastasis. Cell Res. 19, 89\u2013102 (2009).","journal-title":"Cell Res."},{"key":"BFnrd3810_CR34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ceb.2009.01.021","volume":"21","author":"CH Heldin","year":"2009","unstructured":"Heldin, C. H., Landstrom, M. & Moustakas, A. Mechanism of TGF-\u03b2 signaling to growth arrest, apoptosis, and epithelial\u2013mesenchymal transition. Curr. Opin. Cell Biol. 21, 166\u2013176 (2009).","journal-title":"Curr. Opin. Cell Biol."},{"key":"BFnrd3810_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","volume":"347","author":"S Dooley","year":"2012","unstructured":"Dooley, S. & ten Dijke, P. TGF-\u03b2 in progression of liver disease. Cell Tissue Res. 347, 245\u2013256 (2012).","journal-title":"Cell Tissue Res."},{"key":"BFnrd3810_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7150\/ijbs.8.195","volume":"8","author":"E Pardali","year":"2012","unstructured":"Pardali, E. & Ten Dijke, P. TGF\u03b2 signaling and cardiovascular diseases. Int. J. Biol. Sci. 8, 195\u2013213 (2012).","journal-title":"Int. J. Biol. Sci."},{"key":"BFnrd3810_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ng1001-117","volume":"29","author":"R Derynck","year":"2001","unstructured":"Derynck, R., Akhurst, R. J. & Balmain, A. TGF-\u03b2 signaling in tumor suppression and cancer progression. Nature Genet. 29, 117\u2013129 (2001).","journal-title":"Nature Genet."},{"key":"BFnrd3810_CR38","first-page":"1596","volume":"48","author":"RJ Coffey Jr.","year":"1988","unstructured":"Coffey, R. J. Jr. et al. Growth modulation of mouse keratinocytes by transforming growth factors. Cancer Res. 48, 1596\u20131602 (1988).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR39","doi-asserted-by":"publisher","first-page":"12747","DOI":"10.1073\/pnas.0605333103","volume":"103","author":"RR Gomis","year":"2006","unstructured":"Gomis, R. R. et al. A FoxO-Smad synexpression group in human keratinocytes. Proc. Natl Acad. Sci. USA 103, 12747\u201312752 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3810_CR40","doi-asserted-by":"publisher","first-page":"35444","DOI":"10.1074\/jbc.M301413200","volume":"278","author":"PM Siegel","year":"2003","unstructured":"Siegel, P. M., Shu, W. & Massague, J. Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-\u03b2-mediated epithelial cell growth suppression. J. Biol. Chem. 278, 35444\u201335450 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3810_CR41","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/ng.2366","volume":"44","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst, R. J. The paradoxical TGF-\u03b2 vasculopathies. Nature Genet. 44, 838\u2013839 (2012).","journal-title":"Nature Genet."},{"key":"BFnrd3810_CR42","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure \u2014 an obstacle in cancer therapy. Nature Rev. Cancer 4, 806\u2013813 (2004).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrd3810_CR43","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704\u2013715 (2008).","journal-title":"Cell"},{"key":"BFnrd3810_CR44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/labinvest.3700252","volume":"85","author":"AV Salnikov","year":"2005","unstructured":"Salnikov, A. V. et al. Inhibition of TGF-\u03b2 modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab. Invest. 85, 512\u2013521 (2005).","journal-title":"Lab. Invest."},{"key":"BFnrd3810_CR45","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0002-9440(10)62351-6","volume":"166","author":"BC Willis","year":"2005","unstructured":"Willis, B. C. et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-\u03b21: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 166, 1321\u20131332 (2005).","journal-title":"Am. J. Pathol."},{"key":"BFnrd3810_CR46","doi-asserted-by":"publisher","first-page":"13180","DOI":"10.1073\/pnas.0605669103","volume":"103","author":"KK Kim","year":"2006","unstructured":"Kim, K. K. et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl Acad. Sci. USA 103, 13180\u201313185 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3810_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tcm.2009.01.001","volume":"18","author":"MJ Goumans","year":"2008","unstructured":"Goumans, M. J., van Zonneveld, A. J. & ten Dijke, P. Transforming growth factor \u03b2-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc. Med. 18, 293\u2013298 (2008).","journal-title":"Trends Cardiovasc. Med."},{"key":"BFnrd3810_CR48","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1172\/JCI200319270","volume":"112","author":"M Sato","year":"2003","unstructured":"Sato, M., Muragaki, Y., Saika, S., Roberts, A. B. & Ooshima, A. Targeted disruption of TGF-\u03b21\/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 112, 1486\u20131494 (2003).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR49","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.7150\/ijbs.7.1056","volume":"7","author":"HY Lan","year":"2011","unstructured":"Lan, H. Y. Diverse roles of TGF-\u03b2\/Smads in renal fibrosis and inflammation. Int. J. Biol. Sci. 7, 1056\u20131067 (2011).","journal-title":"Int. J. Biol. Sci."},{"key":"BFnrd3810_CR50","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/cvr\/cvn355","volume":"81","author":"EH Yao","year":"2009","unstructured":"Yao, E. H. et al. A pyrrole-imidazole polyamide targeting transforming growth factor-\u03b21 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc. Res. 81, 797\u2013804 (2009). This study evaluates the potential use of a pyrrole-imidazole polyamide that targets TGFB1 expression for preventing restenosis after the use of drug-eluting stents.","journal-title":"Cardiovasc. Res."},{"key":"BFnrd3810_CR51","doi-asserted-by":"publisher","first-page":"H540","DOI":"10.1152\/ajpheart.91478.2007","volume":"297","author":"S Tsai","year":"2009","unstructured":"Tsai, S. et al. TGF-\u03b2 through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation. Am. J. Physiol. Heart Circ. Physiol. 297, H540\u2013H549 (2009). This study demonstrates the role of the TGF\u03b2\u2013SMAD3 pathway in the development of intimal hyperplasia in response to endothelial injury.","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"BFnrd3810_CR52","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1161\/ATVBAHA.107.158030","volume":"28","author":"K Fu","year":"2008","unstructured":"Fu, K. et al. SM16, an orally active TGF\u03b2 type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arterioscler. Thromb. Vasc. Biol. 28, 665\u2013671 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrd3810_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.devcel.2006.05.011","volume":"11","author":"G Nishimura","year":"2006","unstructured":"Nishimura, G. et al. \u03b4EF1 mediates TGF-\u03b2 signaling in vascular smooth muscle cell differentiation. Dev. Cell 11, 93\u2013104 (2006).","journal-title":"Dev. Cell"},{"key":"BFnrd3810_CR54","doi-asserted-by":"publisher","first-page":"12215","DOI":"10.1073\/pnas.92.26.12215","volume":"92","author":"RJ Diebold","year":"1995","unstructured":"Diebold, R. J. et al. Early-onset multifocal inflammation in the transforming growth factor \u03b21-null mouse is lymphocyte mediated. Proc. Natl Acad. Sci. USA 92, 12215\u201312219 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3810_CR55","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri2095","volume":"7","author":"YP Rubtsov","year":"2007","unstructured":"Rubtsov, Y. P. & Rudensky, A. Y. TGF\u03b2 signalling in control of T-cell-mediated self-reactivity. Nature Rev. Immunol. 7, 443\u2013453 (2007).","journal-title":"Nature Rev. Immunol."},{"key":"BFnrd3810_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4161\/cc.8.1.7291","volume":"8","author":"S Ramesh","year":"2009","unstructured":"Ramesh, S., Wildey, G. M. & Howe, P. H. Transforming growth factor \u03b2 (TGF\u03b2)-induced apoptosis: the rise and fall of Bim. Cell Cycle 8, 11\u201317 (2009).","journal-title":"Cell Cycle"},{"key":"BFnrd3810_CR57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/ni.1965","volume":"12","author":"T Maruyama","year":"2011","unstructured":"Maruyama, T. et al. Control of the differentiation of regulatory T cells and TH17 cells by the DNA-binding inhibitor Id3. Nature Immunol. 12, 86\u201395 (2011).","journal-title":"Nature Immunol."},{"key":"BFnrd3810_CR58","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/nm1001-1118","volume":"7","author":"L Gorelik","year":"2001","unstructured":"Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-\u03b2 signaling in T cells. Nature Med. 7, 1118\u20131122 (2001). This study shows that T cell-specific blockade of TGF\u03b2 signalling using a dominant negative type II receptor potentiates immune eradication of tumours in mice challenged with live tumour cells.","journal-title":"Nature Med."},{"key":"BFnrd3810_CR59","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/stem.150144","volume":"15","author":"Y Yamaguchi","year":"1997","unstructured":"Yamaguchi, Y., Tsumura, H., Miwa, M. & Inaba, K. Contrasting effects of TGF-\u03b21 and TNF-\u03b1 on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15, 144\u2013153 (1997).","journal-title":"Stem Cells"},{"key":"BFnrd3810_CR60","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.4049\/jimmunol.164.5.2285","volume":"164","author":"K Sato","year":"2000","unstructured":"Sato, K. et al. TGF-\u03b21 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J. Immunol. 164, 2285\u20132295 (2000).","journal-title":"J. Immunol."},{"key":"BFnrd3810_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235\u2013238 (2006).","journal-title":"Nature"},{"key":"BFnrd3810_CR62","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature04754","volume":"441","author":"PR Mangan","year":"2006","unstructured":"Mangan, P. R. et al. Transforming growth factor-\u03b2 induces development of the TH17 lineage. Nature 441, 231\u2013234 (2006).","journal-title":"Nature"},{"key":"BFnrd3810_CR63","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.immuni.2011.03.005","volume":"34","author":"I Gutcher","year":"2011","unstructured":"Gutcher, I. et al. Autocrine transforming growth factor-\u03b21 promotes in vivo TH17 cell differentiation. Immunity 34, 396\u2013408 (2011).","journal-title":"Immunity"},{"key":"BFnrd3810_CR64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cyto.2011.06.009","volume":"56","author":"F Annunziato","year":"2011","unstructured":"Annunziato, F. & Romagnani, S. Mouse T helper 17 phenotype: not so different than in man after all. Cytokine 56, 112\u2013115 (2011).","journal-title":"Cytokine"},{"key":"BFnrd3810_CR65","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1084\/jem.20082286","volume":"206","author":"J Das","year":"2009","unstructured":"Das, J. et al. Transforming growth factor \u03b2 is dispensable for the molecular orchestration of TH17 cell differentiation. J. Exp. Med. 206, 2407\u20132416 (2009).","journal-title":"J. Exp. Med."},{"key":"BFnrd3810_CR66","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature09447","volume":"467","author":"K Ghoreschi","year":"2010","unstructured":"Ghoreschi, K. et al. Generation of pathogenic TH17 cells in the absence of TGF-\u03b2 signalling. Nature 467, 967\u2013971 (2010).","journal-title":"Nature"},{"key":"BFnrd3810_CR67","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ni1197","volume":"6","author":"Y Laouar","year":"2005","unstructured":"Laouar, Y., Sutterwala, F. S., Gorelik, L. & Flavell, R. A. Transforming growth factor-\u03b2 controls T helper type 1 cell development through regulation of natural killer cell interferon-\u03b3. Nature Immunol. 6, 600\u2013607 (2005).","journal-title":"Nature Immunol."},{"key":"BFnrd3810_CR68","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549\u2013555 (2002).","journal-title":"Trends Immunol."},{"key":"BFnrd3810_CR69","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","volume":"16","author":"ZG Fridlender","year":"2009","unstructured":"Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-\u03b2: \u201cN1\u201d versus \u201cN2\u201d TAN. Cancer Cell 16, 183\u2013194 (2009). This study shows that TGF\u03b2 blockade increases neutrophil-attracting chemokines, and 'depolarizes' the invading tumour-associated neutrophils to become more cytotoxic to tumour cells and to express higher levels of pro-inflammatory cytokines.","journal-title":"Cancer Cell"},{"key":"BFnrd3810_CR70","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/oli.2005.15.94","volume":"15","author":"R Schlingensiepen","year":"2005","unstructured":"Schlingensiepen, R. et al. Intracerebral and intrathecal infusion of the TGF-\u03b22-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety. Oligonucleotides 15, 94\u2013104 (2005).","journal-title":"Oligonucleotides"},{"key":"BFnrd3810_CR71","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cytogfr.2005.09.002","volume":"17","author":"KH Schlingensiepen","year":"2006","unstructured":"Schlingensiepen, K. H. et al. Targeted tumor therapy with the TGF-\u03b22 antisense compound AP 12009. Cytokine Growth Factor Rev. 17, 129\u2013139 (2006).","journal-title":"Cytokine Growth Factor Rev."},{"key":"BFnrd3810_CR72","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3171\/jns.1993.78.6.0944","volume":"78","author":"P Jachimczak","year":"1993","unstructured":"Jachimczak, P. et al. The effect of transforming growth factor-\u03b22-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 78, 944\u2013951 (1993).","journal-title":"J. Neurosurg."},{"key":"BFnrd3810_CR73","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1349-7006.2011.01917.x","volume":"102","author":"KH Schlingensiepen","year":"2011","unstructured":"Schlingensiepen, K. H. et al. Transforming growth factor-\u03b22 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 102, 1193\u20131200 (2011).","journal-title":"Cancer Sci."},{"key":"BFnrd3810_CR74","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/noq142","volume":"13","author":"U Bogdahn","year":"2011","unstructured":"Bogdahn, U. et al. Targeted therapy for high-grade glioma with the TGF-\u03b22 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 13, 132\u2013142 (2011). This is the full report of a randomized, open-label, active-controlled, dose-finding Phase IIb study to evaluate the efficacy and safety of trabedersen (AP12009) administered intra-tumourally by convection-enhanced delivery in patients with recurrent or refractory high-grade glioma.","journal-title":"Neuro Oncol."},{"key":"BFnrd3810_CR75","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.0022-202X.2005.23859.x","volume":"125","author":"B Santiago","year":"2005","unstructured":"Santiago, B. et al. Topical application of a peptide inhibitor of transforming growth factor-\u03b21 ameliorates bleomycin-induced skin fibrosis. J. Invest. Dermatol. 125, 450\u2013455 (2005). This is the first evidence that the peptide inhibitor P144 may be efficacious in the treatment of skin fibrosis after topical application.","journal-title":"J. Invest. Dermatol."},{"key":"BFnrd3810_CR76","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1002\/ijc.24656","volume":"125","author":"D Llopiz","year":"2009","unstructured":"Llopiz, D. et al. Peptide inhibitors of transforming growth factor-\u03b2 enhance the efficacy of antitumor immunotherapy. Int. J. Cancer 125, 2614\u20132623 (2009).","journal-title":"Int. J. Cancer"},{"key":"BFnrd3810_CR77","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/cvr\/cvn315","volume":"81","author":"N Hermida","year":"2009","unstructured":"Hermida, N. et al. A synthetic peptide from transforming growth factor-\u03b21 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovascular Res. 81, 601\u2013609 (2009). This study shows that P144 inhibits the TGF\u03b21-dependent signalling pathway and prevents myocardial fibrosis.","journal-title":"Cardiovascular Res."},{"key":"BFnrd3810_CR78","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S1043-4666(03)00101-7","volume":"22","author":"IJ Ezquerro","year":"2003","unstructured":"Ezquerro, I. J. et al. A synthetic peptide from transforming growth factor \u03b2 type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 22, 12\u201320 (2003).","journal-title":"Cytokine"},{"key":"BFnrd3810_CR79","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1158\/0008-5472.CAN-08-0215","volume":"68","author":"JS Nam","year":"2008","unstructured":"Nam, J. S. et al. An anti-transforming growth factor \u03b2 antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68, 3835\u20133843 (2008).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR80","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1476-4598-9-122","volume":"9","author":"V Ganapathy","year":"2010","unstructured":"Ganapathy, V. et al. Targeting the transforming growth factor-\u03b2 pathway inhibits human basal-like breast cancer metastasis. Mol. Cancer 9, 122 (2010).","journal-title":"Mol. Cancer"},{"key":"BFnrd3810_CR81","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1158\/1078-0432.CCR-11-0544","volume":"17","author":"F Bouquet","year":"2011","unstructured":"Bouquet, F. et al. TGF\u03b21 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin. Cancer Res. 17, 6754\u20136765 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd3810_CR82","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/jco.2011.29.15_suppl.3011","volume":"29","author":"J Rodon Ahnert","year":"2011","unstructured":"Rodon Ahnert, J. et al. First human dose (FHD) study of the oral transforming growth factor-\u03b2 receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. J. Clin. Oncol. 29, Abstract 3011 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd3810_CR83","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-540-71279-4_16","volume":"177","author":"KH Schlingensiepen","year":"2008","unstructured":"Schlingensiepen, K. H., Fischer-Blass, B., Schmaus, S. & Ludwig, S. Antisense therapeutics for tumor treatment: the TGF-\u03b22 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res. 177, 137\u2013150 (2008).","journal-title":"Recent Results Cancer Res."},{"key":"BFnrd3810_CR84","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1200\/jco.2012.30.15_suppl.4034","volume":"30","author":"H Oettle","year":"2012","unstructured":"Oettle, H. et al. Final results of a phase I\/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J. Clin. Oncol. 30, Abstract 4034 (2012).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd3810_CR85","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1200\/JCO.2005.05.5335","volume":"24","author":"J Nemunaitis","year":"2006","unstructured":"Nemunaitis, J. et al. Phase II study of belagenpumatucel-L, a transforming growth factor \u03b2-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24, 4721\u20134730 (2006). This paper reports the first Phase II trial of the non-viral, gene-based, allogeneic tumour cell vaccine of antisense TGF\u03b22-transfected NSCLC cells. This vaccine shows great promise in increasing survival rates for NSCLC.","journal-title":"J. Clin. Oncol."},{"key":"BFnrd3810_CR86","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/cgt.2009.15","volume":"16","author":"J Nemunaitis","year":"2009","unstructured":"Nemunaitis, J. et al. Phase II trial of Belagenpumatucel-L, a TGF-\u03b22 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther. 16, 620\u2013624 (2009).","journal-title":"Cancer Gene Ther."},{"key":"BFnrd3810_CR87","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/1538-7445.AM2012-5367","volume":"72","author":"L Bazhenova","year":"2012","unstructured":"Bazhenova, L., Carrier, E., Shawler, D. & Fakhrai, H. Long-term survival in a phase II study of belagenpumatucel-L (antisense TGF\u03b2 vaccine) in non small-cell lung cancer (NSCLC). Cancer Res. 72, Abstract 5367 (2012).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR88","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1167\/iovs.02-0978","volume":"44","author":"AL Mead","year":"2003","unstructured":"Mead, A. L., Wong, T. T., Cordeiro, M. F., Anderson, I. K. & Khaw, P. T. Evaluation of anti-TGF-\u03b22 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci. 44, 3394\u20133401 (2003).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"BFnrd3810_CR89","doi-asserted-by":"crossref","unstructured":"CAT-152 0201 Trabeculectomy Study Group. CAT-152 trabeculectomy study. Ophthalmology 114, 1950 (2007).","DOI":"10.1016\/j.ophtha.2007.07.024"},{"key":"BFnrd3810_CR90","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/art.22289","volume":"56","author":"CP Denton","year":"2007","unstructured":"Denton, C. P. et al. Recombinant human anti-transforming growth factor \u03b21 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192. Arthritis Rheum. 56, 323\u2013333 (2007). This report evaluates CAT-192, a recombinant human antibody that neutralizes TGF\u03b21, in the treatment of early-stage diffuse cutaneous systemic sclerosis and concludes that there is no evidence of efficacy.","journal-title":"Arthritis Rheum."},{"key":"BFnrd3810_CR91","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.2174\/138920111798808392","volume":"12","author":"S Lonning","year":"2011","unstructured":"Lonning, S., Mannick, J. & McPherson, J. M. Antibody targeting of TGF-\u03b2 in cancer patients. Curr. Pharm. Biotechnol. 12, 2176\u20132189 (2011).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"BFnrd3810_CR92","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ki.2011.33","volume":"79","author":"H Trachtman","year":"2011","unstructured":"Trachtman, H. et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-\u03b2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 79, 1236\u20131243 (2011).","journal-title":"Kidney Int."},{"key":"BFnrd3810_CR93","doi-asserted-by":"publisher","first-page":"9028","DOI":"10.1200\/jco.2008.26.15_suppl.9028","volume":"26","author":"JC Morris","year":"2008","unstructured":"Morris, J. C. et al. Phase I\/II study of GC1008: a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J. Clin. Oncol. 26, Abstract 9028 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd3810_CR94","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1158\/1078-0432.CCR-09-1634","volume":"16","author":"Z Zhong","year":"2010","unstructured":"Zhong, Z. et al. Anti-transforming growth factor \u03b2 receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 16, 1191\u20131205 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd3810_CR95","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/0008-5472.CAN-07-2307","volume":"68","author":"LA Van Aarsen","year":"2008","unstructured":"Van Aarsen, L. A. et al. Antibody-mediated blockade of integrin \u03b1v\u03b26 inhibits tumor progression in vivo by a transforming growth factor-\u03b2-regulated mechanism. Cancer Res. 68, 561\u2013570 (2008).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR96","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1172\/JCI0215234","volume":"109","author":"RS Muraoka","year":"2002","unstructured":"Muraoka, R. S. et al. Blockade of TGF-\u03b2 inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551\u20131559 (2002).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR97","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.ajpath.2011.02.039","volume":"178","author":"A Lu","year":"2011","unstructured":"Lu, A., Miao, M., Schoeb, T. R., Agarwal, A. & Murphy-Ullrich, J. E. Blockade of TSP1-dependent TGF-\u03b2 activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am. J. Pathol. 178, 2573\u20132586 (2011).","journal-title":"Am. J. Pathol."},{"key":"BFnrd3810_CR98","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/nrd1580","volume":"3","author":"JM Yingling","year":"2004","unstructured":"Yingling, J. M., Blanchard, K. L. & Sawyer, J. S. Development of TGF-\u03b2 signalling inhibitors for cancer therapy. Nature Rev. Drug Discov. 3, 1011\u20131022 (2004).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd3810_CR99","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1517\/13543770903397400","volume":"19","author":"D Bonafoux","year":"2009","unstructured":"Bonafoux, D. & Lee, W. C. Strategies for TGF-\u03b2 modulation: a review of recent patents. Expert Opin. Ther. Pat. 19, 1759\u20131769 (2009).","journal-title":"Expert Opin. Ther. Pat."},{"key":"BFnrd3810_CR100","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2174\/156800906778742460","volume":"6","author":"EF Saunier","year":"2006","unstructured":"Saunier, E. F. & Akhurst, R. J. TGF\u03b2 inhibition for cancer therapy. Curr. Cancer Drug Targets 6, 519\u2013532 (2006).","journal-title":"Curr. Cancer Drug Targets"},{"key":"BFnrd3810_CR101","first-page":"513","volume":"7","author":"RJ Akhurst","year":"2006","unstructured":"Akhurst, R. J. Large- and small-molecule inhibitors of transforming growth factor-beta signaling. Curr. Opin. Investig. Drugs 7, 513\u2013521 (2006).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrd3810_CR102","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/jid.2011.150","volume":"131","author":"H Washio","year":"2011","unstructured":"Washio, H. et al. Transcriptional inhibition of hypertrophic scars by a gene silencer, pyrrole-imidazole polyamide, targeting the TGF-\u03b21 promoter. J. Invest. Dermatol. 131, 1987\u20131995 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrd3810_CR103","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/mt.2009.263","volume":"18","author":"M Chen","year":"2010","unstructured":"Chen, M. et al. Pretranscriptional regulation of Tgf-\u03b21 by PI polyamide prevents scarring and accelerates wound healing of the cornea after exposure to alkali. Mol. Ther. 18, 519\u2013527 (2010).","journal-title":"Mol. Ther."},{"key":"BFnrd3810_CR104","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2337\/db10-0403","volume":"60","author":"HY Chen","year":"2011","unstructured":"Chen, H. Y. et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60, 590\u2013601 (2011).","journal-title":"Diabetes"},{"key":"BFnrd3810_CR105","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1365-2362.2008.02038.x","volume":"38","author":"S Kapoor","year":"2008","unstructured":"Kapoor, S. Smad7 gene transfer therapy: therapeutic applications beyond colonic fibrosis. Eur. J. Clin. Invest. 38, 876\u2013877; author reply 878\u2013880 (2008).","journal-title":"Eur. J. Clin. Invest."},{"key":"BFnrd3810_CR106","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nbt.1769","volume":"29","author":"C Sheridan","year":"2011","unstructured":"Sheridan, C. Gene therapy finds its niche. Nature Biotech. 29, 121\u2013128 (2011).","journal-title":"Nature Biotech."},{"key":"BFnrd3810_CR107","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","volume":"31","author":"AE Foster","year":"2008","unstructured":"Foster, A. E. et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-\u03b2 receptor. J. Immunother. 31, 500\u2013505 (2008).","journal-title":"J. Immunother."},{"key":"BFnrd3810_CR108","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/cgt.2011.83","volume":"19","author":"N Rainusso","year":"2012","unstructured":"Rainusso, N. et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 19, 212\u2013217 (2012).","journal-title":"Cancer Gene Ther."},{"key":"BFnrd3810_CR109","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/mt.2011.131","volume":"19","author":"Y Nakazawa","year":"2011","unstructured":"Nakazawa, Y. et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol. Ther. 19, 2133\u20132143 (2011).","journal-title":"Mol. Ther."},{"key":"BFnrd3810_CR110","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/1078-0432.CCR-09-1322","volume":"16","author":"N Ahmed","year":"2010","unstructured":"Ahmed, N. et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16, 474\u2013485 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd3810_CR111","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","volume":"67","author":"N Ahmed","year":"2007","unstructured":"Ahmed, N. et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 67, 5957\u20135964 (2007).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR112","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2310\/7750.2010.09069","volume":"14","author":"HG Laverty","year":"2010","unstructured":"Laverty, H. G. et al. Effects of avotermin (transforming growth factor \u03b23) in a clinically relevant pig model of long, full-thickness incisional wounds. J. Cutan. Med. Surg. 14, 223\u2013232 (2010).","journal-title":"J. Cutan. Med. Surg."},{"key":"BFnrd3810_CR113","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nm1536","volume":"13","author":"RD Cohn","year":"2007","unstructured":"Cohn, R. D. et al. Angiotensin II type 1 receptor blockade attenuates TGF-\u03b2-induced failure of muscle regeneration in multiple myopathic states. Nature Med. 13, 204\u2013210 (2007).","journal-title":"Nature Med."},{"key":"BFnrd3810_CR114","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1172\/JCI46215","volume":"122","author":"M Podowski","year":"2012","unstructured":"Podowski, M. et al. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J. Clin. Invest. 122, 229\u2013240 (2012).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR115","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1172\/JCI41709","volume":"120","author":"TV Lanz","year":"2010","unstructured":"Lanz, T. V. et al. Angiotensin II sustains brain inflammation in mice via TGF-\u03b2. J. Clin. Invest. 120, 2782\u20132794 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR116","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.healun.2004.11.002","volume":"24","author":"H Zhou","year":"2005","unstructured":"Zhou, H., Latham, C. W., Zander, D. S., Margolin, S. B. & Visner, G. A. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J. Heart Lung Transplant. 24, 1577\u20131585 (2005).","journal-title":"J. Heart Lung Transplant."},{"key":"BFnrd3810_CR117","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1465-9921-12-93","volume":"12","author":"H Taniguchi","year":"2011","unstructured":"Taniguchi, H. et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir. Res. 12, 93 (2011).","journal-title":"Respir. Res."},{"key":"BFnrd3810_CR118","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble, P. W. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377, 1760\u20131769 (2011).","journal-title":"Lancet"},{"key":"BFnrd3810_CR119","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nm0195-74","volume":"1","author":"DJ Grainger","year":"1995","unstructured":"Grainger, D. J. et al. The serum concentration of active transforming growth factor-\u03b2 is severely depressed in advanced atherosclerosis. Nature Med. 1, 74\u201379 (1995).","journal-title":"Nature Med."},{"key":"BFnrd3810_CR120","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0092-8674(00)80127-0","volume":"86","author":"W Cui","year":"1996","unstructured":"Cui, W. et al. TGF\u03b21 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86, 531\u2013542 (1996).","journal-title":"Cell"},{"key":"BFnrd3810_CR121","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.4161\/cc.8.20.9727","volume":"8","author":"B Bierie","year":"2009","unstructured":"Bierie, B. & Moses, H. L. Gain or loss of TGF\u03b2 signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 8, 3319\u20133327 (2009).","journal-title":"Cell Cycle"},{"key":"BFnrd3810_CR122","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1172\/JCI37480","volume":"119","author":"B Bierie","year":"2009","unstructured":"Bierie, B. et al. Abrogation of TGF-\u03b2 signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Invest. 119, 1571\u20131582 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR123","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1093\/emboj\/20.7.1663","volume":"20","author":"J Larsson","year":"2001","unstructured":"Larsson, J. et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-\u03b2 type I receptor-deficient mice. EMBO J. 20, 1663\u20131673 (2001).","journal-title":"EMBO J."},{"key":"BFnrd3810_CR124","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1172\/JCI0215970","volume":"109","author":"RJ Akhurst","year":"2002","unstructured":"Akhurst, R. J. TGF-\u03b2 antagonists: why suppress a tumor suppressor? J. Clin. Invest. 109, 1533\u20131536 (2002).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR125","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1172\/JCI200215333","volume":"109","author":"YA Yang","year":"2002","unstructured":"Yang, Y. A. et al. Lifetime exposure to a soluble TGF-\u03b2 antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607\u20131615 (2002). This is the first demonstration that long-term exposure to a TGF\u03b2 antagonist in mice does not manifest any major adverse effects.","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR126","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0192623311416259","volume":"39","author":"MJ Anderton","year":"2011","unstructured":"Anderton, M. J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916\u2013924 (2011).","journal-title":"Toxicol. Pathol."},{"key":"BFnrd3810_CR127","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1080\/01926230701198469","volume":"35","author":"K Frazier","year":"2007","unstructured":"Frazier, K. et al. Inhibition of ALK5 signaling induces physeal dysplasia in rats. Toxicol. Pathol. 35, 284\u2013295 (2007).","journal-title":"Toxicol. Pathol."},{"key":"BFnrd3810_CR128","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/ng.780","volume":"43","author":"DR Goudie","year":"2011","unstructured":"Goudie, D. R. et al. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nature Genet. 43, 365\u2013369 (2011).","journal-title":"Nature Genet."},{"key":"BFnrd3810_CR129","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd3810_CR130","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","volume":"27","author":"JP Arnault","year":"2009","unstructured":"Arnault, J. P. et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 27, e59\u2013e61 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd3810_CR131","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/j.jaad.2003.11.044","volume":"50","author":"AC Esser","year":"2004","unstructured":"Esser, A. C., Abril, A., Fayne, S. & Doyle, J. A. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J. Am. Acad. Dermatol. 50, S75\u2013S77 (2004).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrd3810_CR132","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207\u2013215 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd3810_CR133","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1078-0432.CCR-11-1344","volume":"18","author":"JP Arnault","year":"2012","unstructured":"Arnault, J. P. et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin. Cancer Res. 18, 263\u2013272 (2012).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd3810_CR134","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/onc.2010.215","volume":"29","author":"A Singh","year":"2010","unstructured":"Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741\u20134751 (2010).","journal-title":"Oncogene"},{"key":"BFnrd3810_CR135","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccr.2007.01.013","volume":"11","author":"M Shipitsin","year":"2007","unstructured":"Shipitsin, M. et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259\u2013273 (2007).","journal-title":"Cancer Cell"},{"key":"BFnrd3810_CR136","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.stem.2009.08.018","volume":"5","author":"H Ikushima","year":"2009","unstructured":"Ikushima, H. et al. Autocrine TGF-\u03b2 signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5, 504\u2013514 (2009).","journal-title":"Cell Stem Cell"},{"key":"BFnrd3810_CR137","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.ccr.2010.10.023","volume":"18","author":"J Anido","year":"2010","unstructured":"Anido, J. et al. TGF-\u03b2 receptor inhibitors target the CD44high\/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655\u2013668 (2010). This is a demonstration of the targeting of tumour-initiating cells by TGF\u03b2 blockade in a mouse model of glioblastoma.","journal-title":"Cancer Cell"},{"key":"BFnrd3810_CR138","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ccr.2009.02.011","volume":"15","author":"S Penuelas","year":"2009","unstructured":"Penuelas, S. et al. TGF-\u03b2 increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15, 315\u2013327 (2009).","journal-title":"Cancer Cell"},{"key":"BFnrd3810_CR139","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature08734","volume":"463","author":"K Naka","year":"2010","unstructured":"Naka, K. et al. TGF-\u03b2\u2013FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463, 676\u2013680 (2010). This is a demonstration of the targeting of leukaemia-initiating cells by TGF\u03b2 blockade in a mouse model of chronic myeloid leukaemia.","journal-title":"Nature"},{"issue":"Suppl. 1","key":"BFnrd3810_CR140","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1158\/1538-7445.AM2012-5234","volume":"72","author":"P Bragado","year":"2012","unstructured":"Bragado, P. et al. Microenvironmental signals dictate disseminated tumor cells (DTCs) fate through regulation of TGF\u03b2II and p38\u03b1. Cancer Res. 72 (Suppl. 1), Abstract 5234 (2012).","journal-title":"Cancer Res."},{"issue":"Suppl. 1","key":"BFnrd3810_CR141","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/1538-7445.AM2012-1366","volume":"72","author":"T Biswas","year":"2012","unstructured":"Biswas, T., Yang, J., Zhao, L. & Sun, L. Z. Development of murine models of breast cancer metastasis for the evaluation of the efficacy of TGF-\u03b2 inhibitors as therapeutic agents. Cancer Res. 72 (Suppl. 1), Abstract 1366 (2012).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR142","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1006\/excr.1998.4261","volume":"245","author":"T Ohmori","year":"1998","unstructured":"Ohmori, T., Yang, J. L., Price, J. O. & Arteaga, C. L. Blockade of tumor cell transforming growth factor-\u03b2s enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp. Cell Res. 245, 350\u2013359 (1998).","journal-title":"Exp. Cell Res."},{"key":"BFnrd3810_CR143","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/onc.2010.546","volume":"30","author":"S Ehata","year":"2011","unstructured":"Ehata, S. et al. Transforming growth factor-\u03b2 decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene 30, 1693\u20131705 (2011).","journal-title":"Oncogene"},{"key":"BFnrd3810_CR144","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-0982","volume":"67","author":"B Tang","year":"2007","unstructured":"Tang, B. et al. Transforming growth factor-\u03b2 can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res. 67, 8643\u20138652 (2007).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR145","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","volume":"19","author":"M Quante","year":"2011","unstructured":"Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257\u2013272 (2011).","journal-title":"Cancer Cell"},{"key":"BFnrd3810_CR146","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-04-0632","volume":"10","author":"T Hayashi","year":"2004","unstructured":"Hayashi, T. et al. Transforming growth factor \u03b2 receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin. Cancer Res. 10, 7540\u20137546 (2004). This is the first report of a chemical inhibitor of T\u03b2RI showing antitumour effects via activity on the tumour microenvironment in a mouse model of multiple myeloma.","journal-title":"Clin. Cancer Res."},{"key":"BFnrd3810_CR147","doi-asserted-by":"publisher","first-page":"e10365","DOI":"10.1371\/journal.pone.0010365","volume":"5","author":"A Bandyopadhyay","year":"2010","unstructured":"Bandyopadhyay, A. et al. Doxorubicin in combination with a small TGF\u03b2 inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS ONE 5, e10365 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrd3810_CR148","doi-asserted-by":"publisher","first-page":"e9870","DOI":"10.1371\/journal.pone.0009870","volume":"5","author":"K Takeuchi","year":"2010","unstructured":"Takeuchi, K. et al. TGF-\u03b2 inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS ONE 5, e9870 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrd3810_CR149","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1172\/JCI3523","volume":"103","author":"JJ Yin","year":"1999","unstructured":"Yin, J. J. et al. TGF-\u03b2 signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197\u2013206 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR150","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1111\/j.1349-7006.2010.01606.x","volume":"101","author":"O Shinto","year":"2010","unstructured":"Shinto, O. et al. Combination effect of a TGF-\u03b2 receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice. Cancer Sci. 101, 1846\u20131852 (2010).","journal-title":"Cancer Sci."},{"key":"BFnrd3810_CR151","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1073\/pnas.0611660104","volume":"104","author":"MR Kano","year":"2007","unstructured":"Kano, M. R. et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-\u03b2 signaling. Proc. Natl Acad. Sci. USA 104, 3460\u20133465 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3810_CR152","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/CJI.0b013e3182518e83","volume":"35","author":"Y Liu","year":"2012","unstructured":"Liu, Y. & Zeng, G. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J. Immunother. 35, 299\u2013308 (2012).","journal-title":"J. Immunother."},{"key":"BFnrd3810_CR153","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1158\/1078-0432.CCR-09-1758","volume":"16","author":"L Wang","year":"2010","unstructured":"Wang, L. et al. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor \u03b2-insensitive CD8+ T cells. Clin. Cancer Res. 16, 164\u2013173 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd3810_CR154","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1158\/1535-7163.MCT-06-0109","volume":"5","author":"Q Zhang","year":"2006","unstructured":"Zhang, Q. et al. Blockade of transforming growth factor-\u03b2 signaling in tumor-reactive CD8+ T cells activates the antitumor immune response cycle. Mol. Cancer Ther. 5, 1733\u20131743 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrd3810_CR155","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1158\/1078-0432.CCR-08-0356","volume":"14","author":"A Wallace","year":"2008","unstructured":"Wallace, A. et al. Transforming growth factor-\u03b2 receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin. Cancer Res. 14, 3966\u20133974 (2008). This is the first demonstration of the use of a chemical TGF\u03b2 receptor inhibitor augmenting adoptive T cell therapy via its immunomodulatory effects.","journal-title":"Clin. Cancer Res."},{"key":"BFnrd3810_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/0008-5472.CAN-10-2941","volume":"71","author":"EC Connolly","year":"2011","unstructured":"Connolly, E. C. et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long term T\u03b2RI\/II kinase inhibition with LY2109761. Cancer Res. 71, 1\u201311 (2011).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR157","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1158\/0008-5472.CAN-11-1212","volume":"71","author":"M Zhang","year":"2011","unstructured":"Zhang, M. et al. Blockade of TGF-\u03b2 signaling by the TGF\u03b2R-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 71, 7155\u20137167 (2011).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR158","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/bcr2224","volume":"11","author":"MH Barcellos-Hoff","year":"2009","unstructured":"Barcellos-Hoff, M. H. & Akhurst, R. J. Transforming growth factor-\u03b2 in breast cancer: too much, too late. Breast Cancer Res. 11, 202 (2009).","journal-title":"Breast Cancer Res."},{"key":"BFnrd3810_CR159","doi-asserted-by":"publisher","first-page":"10861","DOI":"10.1158\/0008-5472.CAN-06-2565","volume":"66","author":"J Kirshner","year":"2006","unstructured":"Kirshner, J. et al. Inhibition of transforming growth factor-\u03b21 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 66, 10861\u201310869 (2006).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR160","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1158\/0008-5472.CAN-10-2933","volume":"71","author":"L Zhou","year":"2011","unstructured":"Zhou, L. et al. Reduced SMAD7 leads to overactivation of TGF-\u03b2 signaling in MDS that can be reversed by a specific inhibitor of TGF-\u03b2 receptor I kinase. Cancer Res. 71, 955\u2013963 (2011).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR161","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ccm.2011.11.005","volume":"33","author":"S Cerri","year":"2012","unstructured":"Cerri, S., Spagnolo, P., Luppi, F. & Richeldi, L. Management of idiopathic pulmonary fibrosis. Clin. Chest Med. 33, 85\u201394 (2012).","journal-title":"Clin. Chest Med."},{"key":"BFnrd3810_CR162","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1513\/pats.200601-008AW","volume":"3","author":"D Sheppard","year":"2006","unstructured":"Sheppard, D. Transforming growth factor \u03b2: a central modulator of pulmonary and airway inflammation and fibrosis. Proc. Am. Thorac. Soc. 3, 413\u2013417 (2006).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"BFnrd3810_CR163","doi-asserted-by":"publisher","first-page":"208219","DOI":"10.1155\/2011\/208219","volume":"2011","author":"TR Katsumoto","year":"2011","unstructured":"Katsumoto, T. R., Violette, S. M. & Sheppard, D. Blocking TGF\u03b2 via inhibition of the \u03b1v\u03b26 integrin: a possible therapy for systemic sclerosis interstitial lung disease. Int. J. Rheumatol. 2011, 208219 (2011). This report summarizes the inhibition of \u03b1V\u03b26 integrin as an attractive therapeutic option for systemic sclerosis and interstitial lung disease mediated by TGF\u03b2.","journal-title":"Int. J. Rheumatol."},{"key":"BFnrd3810_CR164","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-physiol-012110-142225","volume":"73","author":"HA Chapman","year":"2011","unstructured":"Chapman, H. A. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu. Rev. Physiol. 73, 413\u2013435 (2011).","journal-title":"Annu. Rev. Physiol."},{"key":"BFnrd3810_CR165","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/1753465812436663","volume":"6","author":"A Azuma","year":"2012","unstructured":"Azuma, A. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 6, 107\u2013114 (2012). This report summarizes the outcome of a number of clinical trials of pirfenidone, which is the first antifibrotic agent to be approved for the treatment of IPF.","journal-title":"Ther. Adv. Respir. Dis."},{"key":"BFnrd3810_CR166","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/jcp.2006.039396","volume":"60","author":"M Yamada","year":"2007","unstructured":"Yamada, M. et al. Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis. J. Clin. Pathol. 60, 916\u2013920 (2007).","journal-title":"J. Clin. Pathol."},{"key":"BFnrd3810_CR167","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cyto.2010.11.019","volume":"53","author":"L Arribillaga","year":"2011","unstructured":"Arribillaga, L. et al. Therapeutic effect of a peptide inhibitor of TGF-\u03b2 on pulmonary fibrosis. Cytokine 53, 327\u2013333 (2011).","journal-title":"Cytokine"},{"key":"BFnrd3810_CR168","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nrd3708","volume":"11","author":"S Crunkhorn","year":"2012","unstructured":"Crunkhorn, S. Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy. Nature Rev. Drug Discov. 11, 260 (2012).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd3810_CR169","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nbt0512-375","volume":"30","author":"M Allison","year":"2012","unstructured":"Allison, M. Stromedix acquisition signals growing interest in fibrosis. Nature Biotech. 30, 375\u2013376 (2012).","journal-title":"Nature Biotech."},{"key":"BFnrd3810_CR170","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/sj.ki.5000054","volume":"69","author":"Y Liu","year":"2006","unstructured":"Liu, Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69, 213\u2013217 (2006).","journal-title":"Kidney Int."},{"key":"BFnrd3810_CR171","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2613.2011.00775.x","volume":"92","author":"M Fragiadaki","year":"2011","unstructured":"Fragiadaki, M. & Mason, R. M. Epithelial-mesenchymal transition in renal fibrosis \u2014 evidence for and against. Int. J. Exp. Pathol. 92, 143\u2013150 (2011).","journal-title":"Int. J. Exp. Pathol."},{"key":"BFnrd3810_CR172","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5114\/aoms.2011.22069","volume":"7","author":"C Alan","year":"2011","unstructured":"Alan, C., Kocoglu, H., Altintas, R., Alici, B. & Resit Ersay, A. Protective effect of decorin on acute ischaemia-reperfusion injury in the rat kidney. Arch. Med. Sci. 7, 211\u2013216 (2011).","journal-title":"Arch. Med. Sci."},{"key":"BFnrd3810_CR173","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1046\/j.1523-1755.2002.0610s1094.x","volume":"61","author":"Y Terada","year":"2002","unstructured":"Terada, Y. et al. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. 61, S94\u2013S98 (2002). This report indicates that genetic transfer of Smad7 prevents unilateral ureteral obstruction-induced renal fibrosis, suggesting that SMAD7 may be applicable for the treatment of renal fibrosis.","journal-title":"Kidney Int."},{"key":"BFnrd3810_CR174","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","volume":"103","author":"DS Lim","year":"2001","unstructured":"Lim, D. S. et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103, 789\u2013791 (2001).","journal-title":"Circulation"},{"key":"BFnrd3810_CR175","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCRESAHA.108.192492","volume":"104","author":"E van Rooij","year":"2009","unstructured":"van Rooij, E. & Olson, E. N. Searching for miR-acles in cardiac fibrosis. Circ. Res. 104, 138\u2013140 (2009).","journal-title":"Circ. Res."},{"key":"BFnrd3810_CR176","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/art.23564","volume":"59","author":"PA Merkel","year":"2008","unstructured":"Merkel, P. A. et al. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis Rheum. 59, 699\u2013705 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrd3810_CR177","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2741\/s23","volume":"1","author":"TA McCaffrey","year":"2009","unstructured":"McCaffrey, T. A. TGF-\u03b2 signaling in atherosclerosis and restenosis. Front. Biosci. (Schol. Ed.) 1, 236\u2013245 (2009).","journal-title":"Front. Biosci. (Schol. Ed.)"},{"key":"BFnrd3810_CR178","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.athoracsur.2004.02.066","volume":"78","author":"R Friedl","year":"2004","unstructured":"Friedl, R. et al. Intimal hyperplasia and expression of transforming growth factor-\u03b21 in saphenous veins and internal mammary arteries before coronary artery surgery. Ann. Thorac. Surg. 78, 1312\u20131318 (2004).","journal-title":"Ann. Thorac. Surg."},{"key":"BFnrd3810_CR179","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/gt.2009.63","volume":"16","author":"P Ranjzad","year":"2009","unstructured":"Ranjzad, P., Salem, H. K. & Kingston, P. A. Adenovirus-mediated gene transfer of fibromodulin inhibits neointimal hyperplasia in an organ culture model of human saphenous vein graft disease. Gene Ther. 16, 1154\u20131162 (2009).","journal-title":"Gene Ther."},{"key":"BFnrd3810_CR180","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jvs.2011.04.037","volume":"54","author":"NK Kapur","year":"2011","unstructured":"Kapur, N. K. et al. Inhibition of transforming growth factor-\u03b2 restores endothelial thromboresistance in vein grafts. J. Vasc. Surg. 54, 1117\u20131123.e1 (2011).","journal-title":"J. Vasc. Surg."},{"key":"BFnrd3810_CR181","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.gde.2007.04.006","volume":"17","author":"F Ramirez","year":"2007","unstructured":"Ramirez, F. & Dietz, H. C. Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr. Opin. Genet. Dev. 17, 252\u2013258 (2007).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"BFnrd3810_CR182","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.1192149","volume":"332","author":"TM Holm","year":"2011","unstructured":"Holm, T. M. et al. Noncanonical TGF\u03b2 signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332, 358\u2013361 (2011). This report demonstrates a significant contribution of the non-canonical TGF\u03b2 signalling pathway to aortic aneurysm progression in MFS.","journal-title":"Science"},{"key":"BFnrd3810_CR183","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0161-6420(01)00997-6","volume":"109","author":"D Siriwardena","year":"2002","unstructured":"Siriwardena, D. et al. Human antitransforming growth factor \u03b22 monoclonal antibody \u2014 a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 109, 427\u2013431 (2002).","journal-title":"Ophthalmology"},{"key":"BFnrd3810_CR184","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.ophtha.2007.03.050","volume":"114","author":"P Khaw","year":"2007","unstructured":"Khaw, P. et al. A phase III study of subconjunctival human anti-transforming growth factor \u03b22 monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 114, 1822\u20131830 (2007). This study reports the results from a Phase III study examining the efficacy of CAT-152, a monoclonal antibody to TGF\u03b22, in preventing the progression of fibrosis in patients undergoing first-time trabeculectomy. The study found no difference between CAT-152 and placebo in preventing the failure of trabeculectomy.","journal-title":"Ophthalmology"},{"key":"BFnrd3810_CR185","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/ICO.0b013e31822018f2","volume":"30","author":"K Fukuda","year":"2011","unstructured":"Fukuda, K., Chikama, T., Takahashi, M. & Nishida, T. Long-term follow-up after lamellar keratoplasty in a patient with bilateral idiopathic corneal keloid. Cornea 30, 1491\u20131494 (2011).","journal-title":"Cornea"},{"key":"BFnrd3810_CR186","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/ncomms1633","volume":"3","author":"M Benzinou","year":"2012","unstructured":"Benzinou, M. et al. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nature Commun. 3, 616 (2012).","journal-title":"Nature Commun."},{"key":"BFnrd3810_CR187","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/ng0297-207","volume":"15","author":"M Bonyadi","year":"1997","unstructured":"Bonyadi, M. et al. Mapping of a major genetic modifier of embryonic lethality in TGF\u03b21 knockout mice. Nature Genet. 15, 207\u2013211 (1997).","journal-title":"Nature Genet."},{"key":"BFnrd3810_CR188","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/13547500601162441","volume":"12","author":"DL Farrington","year":"2007","unstructured":"Farrington, D. L. et al. Development and validation of a phosphorylated SMAD ex vivo stimulation assay. Biomarkers 12, 313\u2013330 (2007).","journal-title":"Biomarkers"},{"key":"BFnrd3810_CR189","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1084\/jem.20060772","volume":"203","author":"W Liu","year":"2006","unstructured":"Liu, W. et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203, 1701\u20131711 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnrd3810_CR190","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.4049\/jimmunol.1003099","volume":"186","author":"SA McClymont","year":"2011","unstructured":"McClymont, S. A. et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186, 3918\u20133926 (2011).","journal-title":"J. Immunol."},{"key":"BFnrd3810_CR191","doi-asserted-by":"publisher","first-page":"6335","DOI":"10.1073\/pnas.0701171104","volume":"104","author":"S You","year":"2007","unstructured":"You, S. et al. Adaptive TGF-\u03b2-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc. Natl Acad. Sci. USA 104, 6335\u20136340 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3810_CR192","first-page":"1127","volume":"7","author":"TM Clay","year":"2001","unstructured":"Clay, T. M., Hobeika, A. C., Mosca, P. J., Lyerly, H. K. & Morse, M. A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7, 1127\u20131135 (2001).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd3810_CR193","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13547500701676019","volume":"13","author":"J Baselga","year":"2008","unstructured":"Baselga, J. et al. TGF-\u03b2 signalling-related markers in cancer patients with bone metastasis. Biomarkers 13, 217\u2013236 (2008).","journal-title":"Biomarkers"},{"key":"BFnrd3810_CR194","first-page":"3408","volume":"119","author":"S Bornstein","year":"2009","unstructured":"Bornstein, S. et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J. Clin. Invest. 119, 3408\u20133419 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR195","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1101\/gad.1413306","volume":"20","author":"SL Lu","year":"2006","unstructured":"Lu, S. L. et al. Loss of transforming growth factor-\u03b2 type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 20, 1331\u20131342 (2006).","journal-title":"Genes Dev."},{"key":"BFnrd3810_CR196","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ccr.2006.07.019","volume":"10","author":"RR Gomis","year":"2006","unstructured":"Gomis, R. R., Alarcon, C., Nadal, C., Van Poznak, C. & Massague, J. C\/EBP\u03b2 at the core of the TGF\u03b2 cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10, 203\u2013214 (2006).","journal-title":"Cancer Cell"},{"key":"BFnrd3810_CR197","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1172\/JCI37815","volume":"119","author":"DS Micalizzi","year":"2009","unstructured":"Micalizzi, D. S. et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-\u03b2 signaling. J. Clin. Invest. 119, 2678\u20132690 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR198","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1172\/JCI36125","volume":"120","author":"A Hannigan","year":"2010","unstructured":"Hannigan, A. et al. Epigenetic downregulation of human disabled homolog 2 switches TGF-\u03b2 from a tumor suppressor to a tumor promoter. J. Clin. Invest. 120, 2842\u20132857 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR199","doi-asserted-by":"publisher","first-page":"8184","DOI":"10.1128\/MCB.22.23.8184-8198.2002","volume":"22","author":"BK Law","year":"2002","unstructured":"Law, B. K. et al. Rapamycin potentiates transforming growth factor \u03b2-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol. Cell. Biol. 22, 8184\u20138198 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrd3810_CR200","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.gde.2008.01.004","volume":"18","author":"JA Engelman","year":"2008","unstructured":"Engelman, J. A. & Settleman, J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr. Opin. Genet. Dev. 18, 73\u201379 (2008).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"BFnrd3810_CR201","doi-asserted-by":"publisher","first-page":"ra84","DOI":"10.1126\/scisignal.2001148","volume":"3","author":"RB Corcoran","year":"2010","unstructured":"Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010).","journal-title":"Sci. Signal."},{"key":"BFnrd3810_CR202","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1172\/JCI43796","volume":"120","author":"M Acharya","year":"2010","unstructured":"Acharya, M. et al. \u03b1v Integrin expression by DCs is required for TH17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 120, 4445\u20134452 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR203","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1172\/JCI43786","volume":"120","author":"AC Melton","year":"2010","unstructured":"Melton, A. C. et al. Expression of \u03b1v\u03b28 integrin on dendritic cells regulates TH17 cell development and experimental autoimmune encephalomyelitis in mice. J. Clin. Invest. 120, 4436\u20134444 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3810_CR204","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cmet.2011.04.013","volume":"14","author":"H Yadav","year":"2011","unstructured":"Yadav, H. et al. Protection from obesity and diabetes by blockade of TGF-\u03b2\/Smad3 signaling. Cell Metab. 14, 67\u201379 (2011).","journal-title":"Cell Metab."},{"key":"BFnrd3810_CR205","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1101\/gad.1350705","volume":"19","author":"J Massague","year":"2005","unstructured":"Massague, J., Seoane, J. & Wotton, D. Smad transcription factors. Genes Dev. 19, 2783\u20132810 (2005).","journal-title":"Genes Dev."},{"key":"BFnrd3810_CR206","doi-asserted-by":"publisher","first-page":"e16421","DOI":"10.1371\/journal.pone.0016421","volume":"6","author":"B Keller","year":"2011","unstructured":"Keller, B. et al. Interaction of TGF\u03b2 and BMP signaling pathways during chondrogenesis. PLoS ONE 6, e16421 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrd3810_CR207","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ydbio.2008.06.022","volume":"321","author":"JA Montero","year":"2008","unstructured":"Montero, J. A., Lorda-Diez, C. I., Ganan, Y., Macias, D. & Hurle, J. M. Activin\/TGF\u03b2 and BMP crosstalk determines digit chondrogenesis. Dev. Biol. 321, 343\u2013356 (2008).","journal-title":"Dev. Biol."},{"key":"BFnrd3810_CR208","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S1097-2765(03)00386-1","volume":"12","author":"MJ Goumans","year":"2003","unstructured":"Goumans, M. J. et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGF\u03b2\/ALK5 signaling. Mol. Cell 12, 817\u2013828 (2003). This study demonstrates that TGF\u03b2 regulates the activation state of the endothelium via two opposing type I receptors, ALK1 and T\u03b2RI (also known as ALK5).","journal-title":"Mol. Cell"},{"key":"BFnrd3810_CR209","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/oli.2006.0053","volume":"17","author":"P Hau","year":"2007","unstructured":"Hau, P. et al. Inhibition of TGF-\u03b22 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I\/II studies. Oligonucleotides 17, 201\u2013212 (2007).","journal-title":"Oligonucleotides"},{"key":"BFnrd3810_CR210","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/nor048","volume":"13","author":"MC Chamberlain","year":"2011","unstructured":"Chamberlain, M. C. Convection-enhanced delivery of a transforming growth factor-\u03b22 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132\u2013142). Neuro Oncol. 13, 558\u2013559; author reply 561\u2013552 (2011).","journal-title":"Neuro Oncol."},{"key":"BFnrd3810_CR211","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/noq142","volume":"13","author":"W Wick","year":"2011","unstructured":"Wick, W. & Weller, M. Trabedersen to target transforming growth factor-\u03b2: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132\u2013142). Neuro Oncol. 13, 559\u2013560; author reply 561\u2013552 (2011).","journal-title":"Neuro Oncol."},{"key":"BFnrd3810_CR212","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11060-012-0826-3","volume":"108","author":"GB Roldan Urgoiti","year":"2012","unstructured":"Roldan Urgoiti, G. B., Singh, A. D. & Easaw, J. C. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J. Neurooncol. 108, 173\u2013177 (2012).","journal-title":"J. Neurooncol."},{"key":"BFnrd3810_CR213","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1200\/jco.2012.30.15_suppl.2042","volume":"30","author":"A Azaro","year":"2012","unstructured":"Azaro, A. et al. The oral transforming growth factor-\u03b2 (TGF-\u03b2) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: the first human dose study. J. Clin. Oncol. 30, Abstract 2042 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"BFnrd3810_CR214","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1111\/j.1524-475X.2011.00711.x","volume":"19","author":"NL Occleston","year":"2011","unstructured":"Occleston, N. L. et al. Discovery and development of avotermin (recombinant human transforming growth factor \u03b23): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 19 (Suppl. 1), S38\u2013S48 (2011).","journal-title":"Wound Repair Regen."},{"key":"BFnrd3810_CR215","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ijc.1289","volume":"93","author":"M Platten","year":"2001","unstructured":"Platten, M. et al. N\u2212[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-\u03b2 relesase and reduces migration and invasiveness of human malignant glioma cells. Int. J. Cancer 93, 53\u201361 (2001).","journal-title":"Int. J. Cancer"},{"key":"BFnrd3810_CR216","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/00003226-200005000-00021","volume":"19","author":"M Isaji","year":"2000","unstructured":"Isaji, M. et al. Inhibitory effects of tranilast on the proliferation and functions of human pterygium-derived fibroblasts. Cornea 19, 364\u2013368 (2000).","journal-title":"Cornea"},{"key":"BFnrd3810_CR217","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/jco.2004.22.14_suppl.3132","volume":"22","author":"KH Schlingensiepen","year":"2004","unstructured":"Schlingensiepen, K. H. et al. The TGF-\u03b21 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies. J. Clin. Oncol. 22, Abstract 3132 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFnrd3810_CR218","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1158\/0008-5472.CAN-06-0068","volume":"66","author":"JS Nam","year":"2006","unstructured":"Nam, J. S. et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor \u03b2 in a mouse model of breast cancer. Cancer Res. 66, 6327\u20136335 (2006).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR219","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/1535-7163.MCT-07-0337","volume":"7","author":"D Melisi","year":"2008","unstructured":"Melisi, D. et al. LY2109761, a novel transforming growth factor \u03b2 receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7, 829\u2013840 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrd3810_CR220","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.22201","volume":"47","author":"E Fransvea","year":"2008","unstructured":"Fransvea, E., Angelotti, U., Antonaci, S. & Giannelli, G. Blocking transforming growth factor-\u03b2 up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47, 1557\u20131566 (2008).","journal-title":"Hepatology"},{"key":"BFnrd3810_CR221","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/hep.23118","volume":"50","author":"A Mazzocca","year":"2009","unstructured":"Mazzocca, A., Fransvea, E., Lavezzari, G., Antonaci, S. & Giannelli, G. Inhibition of transforming growth factor \u03b2 receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50, 1140\u20131151 (2009).","journal-title":"Hepatology"},{"key":"BFnrd3810_CR222","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2008.11.035","volume":"277","author":"B Zhang","year":"2009","unstructured":"Zhang, B., Halder, S. K., Zhang, S. & Datta, P. K. Targeting transforming growth factor-\u03b2 signaling in liver metastasis of colon cancer. Cancer Lett. 277, 114\u2013120 (2009).","journal-title":"Cancer Lett."},{"key":"BFnrd3810_CR223","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1124\/mol.62.1.65","volume":"62","author":"GJ Inman","year":"2002","unstructured":"Inman, G. J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-\u03b2 superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65\u201374 (2002).","journal-title":"Mol. Pharmacol."},{"key":"BFnrd3810_CR224","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/1535-7163.737.3.6","volume":"3","author":"MD Hjelmeland","year":"2004","unstructured":"Hjelmeland, M. D. et al. SB-431542, a small molecule transforming growth factor-\u03b2-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 3, 737\u2013745 (2004).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrd3810_CR225","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1124\/mol.65.3.744","volume":"65","author":"S DaCosta Byfield","year":"2004","unstructured":"DaCosta Byfield, S., Major, C., Laping, N. J. & Roberts, A. B. SB-505124 is a selective inhibitor of transforming growth factor-\u03b2 type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 65, 744\u2013752 (2004).","journal-title":"Mol. Pharmacol."},{"key":"BFnrd3810_CR226","doi-asserted-by":"publisher","first-page":"7954","DOI":"10.1158\/0008-5472.CAN-04-1013","volume":"64","author":"M Uhl","year":"2004","unstructured":"Uhl, M. et al. SD-208, a novel transforming growth factor \u03b2 receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954\u20137961 (2004). This is the first report of the use of a chemical inhibitor of T\u03b2RI showing efficacy in reduced tumour growth and invasion as well as increased immunogenicity in a mouse model of glioblastoma.","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR227","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1158\/1078-0432.CCR-06-0162","volume":"12","author":"R Ge","year":"2006","unstructured":"Ge, R. et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-\u03b2 type I receptor kinase in vivo. Clin. Cancer Res. 12, 4315\u20134330 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd3810_CR228","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1158\/0008-5472.CAN-06-2389","volume":"67","author":"E Suzuki","year":"2007","unstructured":"Suzuki, E. et al. A novel small-molecule inhibitor of transforming growth factor \u03b2 type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res. 67, 2351\u20132359 (2007).","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR229","doi-asserted-by":"publisher","first-page":"10247","DOI":"10.1158\/0008-5472.CAN-08-1494","volume":"68","author":"S Kim","year":"2008","unstructured":"Kim, S. et al. Systemic blockade of transforming growth factor-\u03b2 signaling augments the efficacy of immunogene therapy. Cancer Res. 68, 10247\u201310256 (2008). This is the first demonstration of the use of a chemical TGF\u03b2 receptor inhibitor, acting via its immunomodulatory effects, to enhance the efficacy of an adenovirus expressing IFN\u03b2-based immunotherapy.","journal-title":"Cancer Res."},{"key":"BFnrd3810_CR230","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1021\/jm0509905","volume":"49","author":"F Gellibert","year":"2006","unstructured":"Gellibert, F. et al. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-\u03b2 type I receptor inhibitor. J. Med. Chem. 49, 2210\u20132221 (2006).","journal-title":"J. Med. Chem."},{"key":"BFnrd3810_CR231","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/sj.ki.5002717","volume":"73","author":"M Petersen","year":"2008","unstructured":"Petersen, M. et al. Oral administration of GW788388, an inhibitor of TGF-\u03b2 type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 73, 705\u2013715 (2008).","journal-title":"Kidney Int."},{"key":"BFnrd3810_CR232","doi-asserted-by":"publisher","first-page":"H1415","DOI":"10.1152\/ajpheart.01048.2009","volume":"298","author":"SM Tan","year":"2010","unstructured":"Tan, S. M., Zhang, Y., Connelly, K. A., Gilbert, R. E. & Kelly, D. J. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 298, H1415\u2013H1425 (2010).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."}],"updated-by":[{"DOI":"10.1038\/nrd3878","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T00:00:00Z","timestamp":1350604800000}}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd3810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3810","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T22:44:33Z","timestamp":1687733073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd3810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,24]]},"references-count":232,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["BFnrd3810"],"URL":"https:\/\/doi.org\/10.1038\/nrd3810","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,24]]},"assertion":[{"value":"24 September 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2012","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"On page 7 of the main text, LY2382770 was incorrectly referred to as a pan-TGF\u03b2 ligand-specific blocking antibody; it is a TGF\u03b21 ligand-selective blocking antibody. This has now been corrected online.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}